The purpose of this study is to compare health-related costs and asthma control in ordinary clinical practice during 12 months for Symbicort® given as a low maintenance dose plus as needed compared to a free combination of Pulmicortâ and Oxis® plus Bricanyl® as needed, and Symbicort fixed dosing plus Bricanyl as needed in asthmatic patients not adequately controlled on inhaled glucocorticosteroids alone.

Inclusion Criteria:

• Signed informed consent,
• asthma,
• previously treated with glucocorticosteroids and B2-agonist

Exclusion Criteria:

• History of smoking, pregnancy, any significant disease or disorder which may put the patient at risk because of study participation